At 5 years, overall survival was similar between the revasculariza- tion and medical-therapy groups (88.3% versus 87.8%), as was the incidence of MACE (77.2% versus 75.9%).409 Pa- tients with the most severe CAD were assigned to the CABG stratum and those with the least severe CAD to the PCI stratum. In the PCI stratum, there was no significant differ- ence in primary endpoints between the revascularization group and the medical-therapy group. In the 763 patients randomized to the CABG stratum, survival was similar but AMI less frequent among those assigned to revascularization plus intensive medical therapy compared with intensive medical therapy (10.0% versus 17.6%; P50.003), and the composite endpoints of all-cause death or MI (21.1% versus 29.2%; P50.010) and cardiac death or MI (P50.03) were also less frequent. Compared with those selected for PCI, patients in the CABG stratum had more 3-vessel disease more proximal LAD stenoses .50% (10% versus 19%), and a significantly higher myocardial jeopardy score.409 One-year follow-up data from the SYNTAX study demon- strated a higher rate of repeat revascularization in patients with diabetes mellitus treated with PCI than in those treated with CABG, driven by a tendency for higher repeat revascu- larization rates in those with higher SYNTAX scores under- A large meta-analysis that included the BARI trial but not BARI 2D failed to identify any significant difference in mortality rate after CABG versus PCI for patients with diabetes mellitus.1079 In a more recent, collaborative analysis that pooled patient-level data from 10 randomized trials (again, not including BARI 2D), Hlatky and colleagues found that of the 1233 patients with diabetes mellitus, 23% of those assigned to CABG died, compared with 29% of those assigned to PCI.1080 By contrast, of the 6561 patients without diabetes mellitus, 13% and 14% died, respectively (P50.014 for interaction). 